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Attachment of polysaccharide carriers is increasingly being used to achieve precision delivery 
and improved effectiveness of protein and peptide drugs. Although it is clear that their clinical 
effectiveness relies on the purity and integrity of the conjugate in storage, as well as following 
administration, instability of polysaccharide-based conjugates can reduce the protective efficacy 
of the polymer, which may adversely affect the bioactive’s potency. As a model, these studies used 
dextrin–colistin conjugates, with varying degrees of polymer modification (1, 2.5 and 7.5 mol% 
succinoylation) to assess the effect of storage temperature (− 20, 4, 21 and 37 °C) and duration (up to 
12 months) on saccharide and colistin release and antimicrobial activity. Estimation of the proportion 
of saccharide release (by comparison of area under the curve from size exclusion chromatograms) 
was more pronounced at higher temperatures (up to 3 and 35% at − 20 °C and 37 °C, respectively 
after 12 months), however, repeated freeze–thaw did not produce any measurable release of 
saccharides, while addition of amylase (20, 100, 500 IU/L) caused rapid release of saccharides (> 70% 
total within 24 h). At all temperatures, conjugates containing the lowest degree of succinoylation 
released the highest proportion of free colistin, which increased with storage temperature, however 
no trend in saccharide release was observed. Despite the clear physical effects of prolonged storage, 
antimicrobial activity of all samples was only altered after storage at 37 °C for 12 months (> threefold 
decreased activity). These results demonstrate significant release of saccharides from dextrin–colistin 
conjugates during prolonged storage in buffered solution, especially at elevated temperature, which, 
in most cases, did not affect antimicrobial activity. These findings provide vital information about 
the structure–activity relationship of dextrin–colistin conjugates, prior to full-scale commercial 
development, which can subsequently be applied to other polysaccharide-protein and -peptide 
conjugates.
Since the 1970s, polysaccharides such as dextran, dextrin, hyaluronic acid, hydroxyethyl starch and polysialic 
acid have been investigated as carriers for therapeutic protein and peptide drugs in a wide range of clinical 
applications, including cancer, arthritis, viral infections, and, more recently, tissue repair and bacterial  infection1. 
Polysaccharides possess many favorable features for the targeted delivery of protein and peptide drugs since they 
are biodegradable, hydrophilic and non-toxic. Given the reported potential of non-biodegradable polymers, 
such as polyethylene glycol and polyvinylpyrrolidone, to induce lysosomal storage disease and induce antibody 
 formation2–5, the use of polysaccharides for the delivery of therapeutic proteins and peptides has become increas-
ingly attractive. However, unlike well-defined conventional small molecule drugs, polysaccharide-protein and 
-peptide conjugates are complex mixtures that are not easily separated, identified or characterized. The clinical 
effectiveness of conjugated proteins and peptides relies on the purity and integrity of the conjugate in storage and 
following administration, as well as effective enzyme-triggered restoration of activity at the target site. Instability 
of polymer conjugates can reduce the protective efficacy of the polymer, which may adversely affect the protein 
or peptide’s potency.
Previous studies have shown enhanced drug stability when colistin (also known as polymyxin E) was conju-
gated to  dextrin6 and alginate  oligomer7. Dextrin, a linear polymer of D-glucose with over 95% α-1,4 links, was 
chosen as the carrier for the prototype polysaccharide-polymyxin conjugates because it is rapidly degraded in 
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the body by α-amylase via random degradation of the polyglucose chain to form intermediate oligosaccharides 
and, ultimately, the disaccharides maltose and iso-maltose8. Thus, dextrin–colistin conjugates were designed 
to protect the antibiotic and mask its biological activity during passive targeting to sites of infection, while 
amylase degradation at the target site can reinstate colistin’s antibacterial activity. Modification of the dextrin 
backbone has been shown to delay payload release by amylase degradation of  dextrin6,9,10. Preliminary stability 
studies have been performed in water and phosphate buffer solution (PBS) at 4 and 37 °C using size exclusion 
chromatography (SEC) to characterize the size and relative molecular weight of the conjugated colistin com-
ponent. However, analysis of the polysaccharide’s degradation components has not yet been studied. Typically, 
polysaccharide-protein conjugates, synthesized using non-specific conjugation methods, contain complex mix-
tures of various lengths of oligosaccharides and unconjugated polysaccharide, as well as polydisperse conjugates 
with different conjugation efficiencies and polymer: peptide ratios; making them notoriously challenging to 
characterize. Quantification of released saccharides and colistin will help identify suitable storage conditions and 
support quality control of polysaccharide conjugates, to ensure compliance with manufacturing specifications 
and batch-to-batch consistency.
This study assessed the thermostability of dextrin–colistin conjugates containing dextrin with 1, 2.5 and 
7.5 mol% succinoylation, in terms of saccharide and colistin release. For comparison, colistimethate sodium 
(CMS, also known as colistin methanesulfonate,  Colomycin®) and amylase-degraded conjugates were also ana-
lyzed. Since variation in the purity and integrity of polymer-protein and -peptide conjugates may affect their 
potency, antimicrobial activity of antibiotic solutions after storage for 12 months at varying temperatures was 
also determined.
Results
Thermostability during storage. To assess the integrity and size of dextrin–colistin conjugates during 
storage, size exclusion chromatography with RI and UV absorbance (at 210 and 280 nm) detection was per-
formed using FPLC and GPC systems. When stored samples were eluted through an Ultrahydrogel 120 column, 
colistin sulfate showed a small peak at ~ 12 mL and a larger peak at ~ 14 mL (Fig. 1, S1). Apart from an increased 
intensity of the peak corresponding to salts (~ 17.5 mL), colistin’s elution profile was largely unchanged after 
storage. Significant changes in the elution profile of CMS were observed after storage above − 20 °C. dextrin–
colistin conjugate samples had a characteristically similar elution profile, with a large peak of high molecular 
weight material eluting in the void volume (~ 12 mL), followed by a series of smaller peaks that appeared or 
grew larger during storage (Fig. 1, S1). The appearance of additional, low molecular weight peaks was more 
pronounced at higher temperatures. When the area under the curve of peaks with molecular weight < 800, cor-
responding to oligo- and disaccharides, was used to estimate the proportion of released saccharides, time- and 
temperature-dependent release of sugars was observed (Fig. 2). Higher saccharide release was observed from 
conjugates containing 2.5 mol% dextrin at all storage temperatures, compared to 1 and 7.5 mol% (Figs. 1, 2).
When stored samples were eluted through a Superdex 75 column, colistin sulfate gave a single peak at ~ 17 mL, 
while the elution profile of CMS had multiple peaks that changed in size during storage (Fig. 3). Dextrin–colistin 
conjugates had a broad peak that started in the void volume (~ 8 mL) and a second, small peak at the same elution 
volume as unmodified colistin (~ 17 mL). Conjugates containing dextrin with a higher degree of succinoylation 
had a more prominent peak in the void volume, while conjugates containing dextrin with a lower degree of 
succinoylation had a broader peak corresponding to the conjugate. Conjugate elution pattern was maintained 
when samples were stored at − 20 °C, while appearance or growth of a peak at ~ 17 mL was evident after storage 
at 4, 21 and 37 °C. When the area under the curve for the peak at ~ 17 mL, corresponding to free colistin, was 
used to estimate the proportion of released colistin, time- and temperature-dependent release of colistin was 
observed (Fig. 4). Under each storage condition, conjugates containing the lowest degree of succinoylation had 
the highest proportion of free colistin.
When dextrin–colistin conjugates were subjected to repeated freeze–thaw, no measurable release of sac-
charides was observed (Fig. 1). Nevertheless, a peak corresponding to free colistin appeared after repeated 
freeze–thaw and was largest for conjugates containing dextrin with the lowest degree of succinoylation (Fig. 4d).
Antimicrobial activity of the test compounds following repeated freeze–thaw or storage in solution for up 
to 12 months was assessed by minimum inhibitory concentration (MIC) assay. As observed previously, the 
antimicrobial activity of dextrin–colistin conjugates was lower than colistin sulfate and CMS, and decreased 
further with increasing degree of succinoylation (Table 1). Antimicrobial activity of colistin sulfate, CMS and the 
dextrin–colistin conjugates was unaffected by repeated freeze–thaw or storage in solution for up to 12 months 
at − 20, 4 or 21 °C. However, when antibiotic solutions were stored at 37 °C for 12 months, a significant decrease 
in antimicrobial activity was observed (> threefold).
Degradation of dextrin-colistin conjugates by amylase. Release of saccharides during amylase-
degradation of the dextrin-colistin conjugates was assessed using GPC (Fig. 5). Less than 2.6% of total AUC cor-
responded to free saccharides when conjugates were incubated at 37 °C for up to 168 h in the absence of amylase, 
however, addition of amylase caused rapid release of saccharides, which was greatest for conjugates containing 
dextrin with the lowest degree of succinoylation (Fig. 6). Increasing amylase concentration from 20 to 500 IU/L 
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Discussion
Studies to investigate the stability of colistin and CMS in aqueous media have, to date, mostly been limited to 
just a few days or  weeks11–13. Here, we have investigated the thermostability of colistin sulfate, CMS (a complex 
mixture of methane sulfonated colistin derivatives) and dextrin-colistin conjugates during long-term storage 
in buffered solution.
Dextrin-colistin conjugates were developed, in part, to overcome the spontaneous hydrolysis of CMS to par-
tial sulfomethyl derivatives and colistin in aqueous solution, which may result in accidental administration of 
elevated levels of colistin. For this reason, it is recommended that CMS should be reconstituted in sterile water 
Figure 1.  GPC chromatograms showing refractive index (RI) of (a) colistin sulfate, (b) colistimethate sodium 
(CMS) and dextrin–colistin conjugates with (c) 1 mol%, (d) 2.5 mol% and (e) 7.5 mol% succinoylation before 
(dotted line) and following storage at − 20 (dark blue line), 4 (light blue line), 21 (yellow line) or 37 (red line)°C 
for 12 months, or exposed to weekly freeze-thawing for 5 weeks (pink line).
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no more than 24 h prior to  administration14. Here, hydrolysis of CMS during storage in PBS buffer, even at 4 °C 
and after repeated freeze–thaw, was evident from the altered FPLC elution profiles. Although previous studies 
have used much shorter storage durations they agree that CMS hydrolyses faster at higher temperatures and in 
salt  solutions11–13.
In this study, dextrin-colistin conjugates were dissolved and stored in PBS at pH 7.4, since this is a common 
diluent for in vitro experiments and it is representative of the pH of tissues it would reside in after intravenous 
Figure 2.  Release of free saccharides from dextrin–colistin conjugates with (a) 1 mol%, (b) 2.5 mol% and (c) 
7.5 mol% succinoylation following storage at − 20 (dark blue circle), 4 (light blue square), 21 (orange triangle) or 
37 (red diamond)°C for up to 12 months.
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(IV) administration. This is also close to the optimum pH for α-amylase optimal enzyme activity (6.7–7.0)15. 
Degradation of polysaccharides in alkaline solution is well known, generally occurring at the reducing end of 
the polymer and proceeding stepwise along the  chain16. Studies show that alkaline degradation of glycans con-
taining 14 linkages, such as dextrin, produces isosaccharinates, following a rearrangement to a ketose  form16. 
Although temperature is known to affect the speed of polysaccharide degradation, it does not affect the nature 
or proportion of the degradation products and there is typically minimal degradation at low temperatures 
(< 25 °C)16–18. Even though pH 7.4 is only slightly alkaline, significant degradation of dextrin was observed 
Figure 3.  FPLC chromatograms showing absorbance at 210 nm of (a) colistin sulfate, (b) colistimethate sodium 
(CMS) and dextrin–colistin conjugates with (c) 1 mol%, (d) 2.5 mol% and (e) 7.5 mol% succinoylation before 
(dotted line) and following storage at −  20 (dark blue line), 4 (light blue line), 21 (yellow line) or 37 (red line)°C 
for 12 months or exposed to weekly freeze-thawing for 5 weeks (pink line).
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during prolonged incubation of dextrin-colistin conjugates in PBS buffer at elevated temperatures. GPC chroma-
tograms of conjugate samples stored for up to 12 months show the appearance of several peaks with molecular 
weights corresponding to maltotetraose (667), maltotriose (504) and maltose (360). As storage temperature and 
duration increased, the peaks corresponding to maltose and smaller oligosaccharides became more prominent, 
suggestive of further degradation of larger oligosaccharides and polymers. Unexpectedly, conjugates containing 
2.5 mol% succinoylation released more saccharides than those containing 1 or 7.5 mol% succinoylated dextrin. 
The reason for this is unclear and does not appear to be related to concentration, drug loading, molecular weight 
or size. We hypothesize that the spacing between succinoylated sugars may affect the rate and extent of dextrin 
degradation, whereby the steric effects of 2.5 mol% succinoylation is optimal for enzyme activity. Alternatively, 
the 2.5 mol% succinoylation may create an optimum pH in the microenvironment at the surface of the polymer 
which maximizes amylase’s catalytic rate by influencing enzymatic substrate accumulation and equilibrium 
constants of the reaction. Further studies to confirm and investigate this observation are ongoing. The presence 
of an alkali-resistant linkage in the polysaccharide can interrupt alkaline degradation before complete degrada-
tion is  achieved18, however it does not appear that succinoylation has a noticeable effect on alkaline degradation 
under the conditions tested here.
After IV administration, dextrin-colistin conjugates would be exposed to α-amylase, an endoamylase that 
cleaves dextrin within the polyglucose chain, in the bloodstream. Previous studies have shown that the antimi-
crobial activity of dextrin-colistin conjugates was greatest when colistin was attached to shorter chains of dextrin 
with minimal modification by  succinoylation19. Here, we have shown rapid concentration-dependent release of 
low molecular weight oligosaccharides and maltose in the presence of α-amylase, which was greatest for conju-
gates with the lowest degree of succinoylation. After an initial burst of saccharide release, the total proportion 
of released sugars from 1, 2.5 and 7.5 mol% conjugates reached a plateau at ~ 41, ~ 37 and ~ 30%, respectively. 
Figure 4.  Release of free colistin from dextrin–colistin conjugates with (a) 1 mol%, (b) 2.5 mol% and (c) 
7.5 mol% succinoylation following storage at -20 (dark blue circle), 4 (light blue square), 21 (orange triangle) 
or 37 (red diamond)°C for up to 12 months. Panel (d) shows release of free colistin from dextrin–colistin 
conjugates before and after exposure to weekly freeze-thawing for 5 weeks.
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This supports the premise that residual chains of dextrin attached to colistin in conjugates with higher degrees 
of succinoylation obstruct its antimicrobial  activity19.
Detection of colistin can be achieved using several methods, including chromatography with fluorescence 
after  derivatization20–23 or mass  spectrometry19,24–27 detection, microbiological  assays28,29, enzyme-linked 
(ELISA)6,30 and derivative  spectrophotometry31. Here, analysis of FPLC chromatograms was achieved by moni-
toring absorbance at 210 nm. Storage of conjugate solutions above 4 °C caused an increase in the amount of free 
colistin detected, which increased with storage temperature and was lowest for conjugates containing dextrin 
with higher degrees of succinoylation. Analysis of the area under the curve of peaks corresponding to dextrin-
colistin conjugate and free colistin suggests that almost complete release of colistin was reached within 3 month 
when conjugates were stored at 37 °C and within 12 months when they were stored at 21 °C. However, even 
for colistin sulfate and CMS solutions, the total AUC of all peaks increased with storage time and temperature 
(Fig. 3), meaning that these estimates are unreliable. It is unclear why absorbance at 210 nm by the stored solu-
tions increased over time and at increased temperature. Analysis of the same samples by GPC showed a large peak 
corresponding to high molecular weight conjugate by RI (Fig. 1, S1), as well as absorbance at 210 nm (data not 
shown) detection, indicating the presence of high molecular weight species containing both dextrin and colistin, 
even after 12 months storage. It is unlikely that solute evaporation caused the observed increase in colistin’s UV 
absorbance at higher storage temperatures, because no noticeable volume reduction was observed from tightly 
sealed tubes. Instead, it is reasonable to assume that prolonged storage of samples at 21 and 37 °C caused changes 
to colistin’s secondary structure that altered its UV absorption. Alternatively, variation in counterion concen-
tration can lead to increased UV absorbance. Previous studies have shown that UV absorbance of the peptide 
bond (200–230 nm) in a 33.5 μM α-synuclein solution decreased with increasing counterion  concentration32.
Reassuringly, despite apparent degradation of dextrin-colistin conjugates during storage above 4 °C, anti-
microbial activity was only reduced when conjugates were stored for 12 months at 37 °C. This trend was also 
observed for colistin sulfate and CMS. Although relatively less degradation of the conjugates occurred after 
repeated freeze–thaw of stock solutions (compared to during incubation with amylase or after prolonged storage 
above 4 °C), this was not associated with diminished antimicrobial activity. In this study, it was not possible to 
obtain MIC values above 128 mg/L as stored samples were prepared at 3 mg/mL conjugate, which limited the 
maximum colistin concentration that could be tested. However, in agreement with previous  studies6, antimicro-
bial activity of dextrin-colistin conjugates decreased with increasing degree of dextrin succinoylation. It is not 
clear, from this study or from previous research, whether degradation of dextrin-colistin conjugates occurs during 
the incubation period of MIC assay experiments. Previous studies showed that pre-incubation of conjugates with 
amylase at equivalent concentrations as that found in human serum (100 IU/L) did not alter their antimicrobial 
 potency5. Although the bacterial strains tested here do not secrete amylase (measured by Phadebas assay, data 
not shown), it is likely that other metabolic enzymes in the culture medium or secreted by the bacteria, as well 
as incubation at 37 °C for 16–20 h, would, at least partially, degrade dextrin. When Varache et al.19 tested the 
antimicrobial activity of differentially degraded fractions of dextrin-colistin conjugates, they found that antimi-
crobial activity was greatest for fully ‘unmasked’ conjugates, so further degradation of the conjugates during the 
MIC assay, or in vivo, at sites of inflammation/ infection, would be expected to enhance its antimicrobial activity.
In clinical practice, it is unlikely that antibiotic solutions would be stored for prolonged periods at elevated 
temperatures, as used in this study. Lyophilized samples of dextrin-colistin conjugates are stable for at least 
Table 1.  Antimicrobial activity of colistin sulfate, CMS and dextrin–colistin conjugates following storage at 
-20, 4, 21 or 37 °C for 12 months or exposed to weekly freeze-thawing for 5 weeks, measured by MIC assay. 





Repeat freeze–thaw-20 4 21 37
V5 E. coli AIM-1
Colistin sulfate 0.004 0.002 0.002 0.016 0.25 0.004
CMS 0.125 0.031 0.063 0.063 8 0.031
Dextrin–colistin 1 mol% 1 1 1 4  > 128 0.5
Dextrin–colistin 2.5 mol% 1 2 1 4  > 128 0.5
Dextrin–colistin 7.5 mol% 8 16 4 16  > 128 4
V6 K. pneumoniae IR25
Colistin sulfate 0.125 0.063 0.125 0.5  > 128 0.25
CMS 2 1 1 1 128 0.5
Dextrin–colistin 1 mol% 64 128 128 128  > 128 64
Dextrin–colistin 2.5 mol%  > 128  > 128  > 128  > 128  > 128 64
Dextrin–colistin 7.5 mol%  > 128  > 128  > 128  > 128  > 128  > 128
V19 A. baumannii 7789
Colistin sulfate 0.063 0.063 0.031 0.125 32 0.063
CMS 0.5 0.25 0.125 0.25 64 0.125
Dextrin–colistin 1 mol% 64 128 64  > 128  > 128 16
Dextrin–colistin 2.5 mol% 128 128 64  > 128  > 128 32
Dextrin-colistin 7.5 mol%  > 128  > 128  > 128  > 128  > 128 128
8
Vol:.(1234567890)
Scientific Reports |        (2021) 11:10600  | https://doi.org/10.1038/s41598-021-89946-2
www.nature.com/scientificreports/
12 months, with no effect on structural stability or antimicrobial potency (data not shown). All dextrin-colistin 
conjugates were stable when stored in solution at − 20 °C for up to 12 months, however repeat freeze–thaw 
resulted in detectable levels of released colistin. These findings suggest that aliquots of stock solutions of conju-
gates can be safely stored at or below − 20 °C for up to 12 months, however, repeat freeze–thaw should be avoided.
This study has developed and validated a method to test the thermostability of dextrin-colistin conjugates, 
which can subsequently be applied to other polysaccharide-protein and -peptide conjugates. This methodology 
will provide crucial understanding of the rate and extent of saccharide release during storage and in physiologi-
cal solutions containing amylase. This study has verified the purity and integrity of dextrin-colistin conjugates 
currently in pre-clinical development, prior to full-scale commercial development.
Materials and methods
Materials. Type I dextrin from corn  (Mw = 7500), colistin sulfate, α-amylase from human saliva, N-hydrox-
ysulfosuccinimide (sulfo-NHS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), bicin-
choninic acid (BCA) solution, dimethyl sulfoxide (DMSO), glucose and maltose oligomers (DP 2, 3, 6 and 7) 
were purchased from Sigma-Aldrich (Poole, UK). 1-Ethyl-3-(3-(dimethylamino)propyl carbodiimide hydro-
chloride) (EDC) was acquired from Pierce (Rockford, USA). Disodium hydrogen phosphate, potassium dihy-
drogen phosphate, potassium chloride, 4-dimethylaminopyridine (DMAP), and sodium chloride were from 
Fisher Scientific (Loughborough, UK). Unless otherwise stated, all chemicals were of analytical grade and used 
as received. All solvents were of general reagent grade (unless stated) and were from Fisher Scientific (Loughbor-
ough, UK). Colistimethate sodium (CMS, Colomycin®) was from Teva UK Limited (Eastbourne, UK).
Bacterial culture. The clinical isolates (V5 Escherichia coli AIM-1, V6 Klebsiella pneumoniae IR25 and V19 
Acinetobacter baumannii 7789) and susceptibility testing method have been previously described by Khan et al.33 
Bacterial colonies were grown on blood agar supplemented with 5% v/v defibrinated horse blood. Overnight 
Figure 5.  GPC chromatograms showing refractive index (RI) of dextrin-colistin conjugates with (a-c) 1 mol%, 
(d-f) 2.5 mol% and (g-i) 7.5 mol% succinoylation following incubation with amylase (0, 20, 100 and 500 IU/L) 
at 37 °C for 0 (dotted line), 2 (red line), 6 (yellow line), 8 (dark blue line), 24 (green line), 48 (pink line), 72 (light 
blue line) and 168 (brown line) h.
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cultures were prepared in tryptone soy broth (TSB) and Mueller–Hinton broth (MHB) was used for MIC deter-
mination (LabM; Bury, UK).
Synthesis of dextrin‑colistin conjugates. Dextrin-colistin conjugates, having 1, 2.5 and 7.5 mol% succinoylation 
of dextrin (Mw = 7500; degree of polymerization (DP) = 50), were synthesized using EDC and sulfo-NHS, puri-
fied by fast protein liquid chromatography (FPLC) using a HiLoad 16/600 Superdex 75 column and character-
ized according to previously optimized  methods11. Molecular weight was determined using a Viscotek TDA302 
triple detector system, equipped with integrated refractive index (RI), viscometer and light scattering (LALS 
Figure 6.  Release of free saccharides from dextrin-colistin conjugates with (a) 1 mol%, (b) 2.5 mol% and (c) 
7.5 mol% succinoylation following incubation with amylase (0 (black diamond), 20 (red circle), 100 (green 
square) and 500 (dark blue triangle) IU/L) at 37 °C for up to 168 h.
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and RALS) detection and a Viscotek 2501 UV detector (210 nm). The column set consisted of an Ultrahydrogel 
guard column and two Ultrahydrogel 250 columns (7.8 mm × 300 mm) from Waters (Elstree, UK) in series, 
running at 30 °C with PBS buffer eluent and a flow rate of 0.7 mL/min. Samples (300 μL) were injected into a 
100 μL loop. A polyethylene oxide standard (Mw = 23,964, Mn = 23,502, IV = 0.404) from Malvern Panalytical 
(Malvern, UK) was employed for the calibration set up. The characteristics of dextrin-colistin conjugates used in 
these studies are summarized in Table 2.
Stability sample preparation. Stability during storage. Three primary batches of colistin sulfate, CMS 
and dextrin-colistin conjugates were dissolved in PBS at 3 mg/mL and stored at − 20, 4, 21 and 37 °C for 0, 1, 3, 
6, 9 and 12 months. In addition, to test the effect of repeated freeze–thaw on stability, a separate set of solutions 
were stored at − 20 °C and defrosted for 1 h at 20–22 °C weekly for 5 cycles. Samples were analyzed using FPLC 
(free drug) and GPC (saccharide release) and antimicrobial activity, UV/vis absorbance and protein content 
(bicinchoninic acid (BCA) assay) of the samples stored for 12 months was assessed.
Fast protein liquid chromatography. FPLC was performed using an ÄKTA Purifier from GE Healthcare (Amer-
sham, UK) column with a UV detector and data analysis using Unicorn 5.31 software from GE Healthcare 
(Amersham, UK). Samples (200 μL) were injected into a 100 μL loop at 0.5 mL/min, connected to a prepacked 
Superdex 75 10/300 GL column with PBS buffer eluent. The proportion of free colistin was calculated by inte-
grating the peaks corresponding to conjugate and free drug.
Gel permeation chromatography. GPC was performed using an Ultrahydrogel guard column and two Ultrahy-
drogel 120 columns (7.8 mm × 300 mm) from Waters (Elstree, UK) in series, connected to a Jasco PU-1580 
HPLC pump with PBS buffer eluent and a flow rate of 1 mL/min. Samples (300 μL) were injected into a 100 μL 
loop and the eluate was monitored using a Jasco MD-2010 multi-wavelength UV detector (210 and 280 nm) and 
a Gilson 153 differential refractometer (Middleton, WI, USA) connected to a Polymer Laboratories PL Data-
Stream (Church Stretton, UK). Dual detection enabled distinction of dextrin and saccharide components that 
are not bound to colistin. Cirrus GPC software (version 3.2, 2006) from Polymer Laboratories (Church Stretton, 
UK) was used for data analysis. Glucose and maltose oligomers (DP 2, 3, 6 and 7) were employed for calibration. 
Area under the curve of peaks corresponding to maltose, maltotriose and maltotetraose were used to calculate 
the proportion of free saccharides, compared to total AUC of all peaks with molecular weight > 300.
Antimicrobial activity. The minimum inhibitory concentration (MIC) of colistin sulphate, CMS and dextrin-
colistin conjugates was determined using the broth microdilution method in MH broth in accordance with 
standard  guidelines34. Test organisms were suspended in MH broth (100 µL, 5 ×  105 colony forming units (CFU)/
mL) and incubated in 96-well microtitre plates in serial two-fold dilutions of the test compounds. The MIC was 
defined as the lowest concentration of test compound that produced no visible growth after 16–20 h. Results 
were expressed as mode (n = 3).
Degradation of dextrin‑colistin conjugates by amylase.. Dextrin-colistin conjugates were dissolved in PBS 
(3 mg/mL colistin base in PBS, pH 7.4) containing amylase (0, 20, 100 and 500 IU/L) and incubated at 37 °C for 
0, 2, 6, 12, 24, 48, 72, 168 h. Samples were analyzed using FPLC and GPC, as described previously.
Received: 29 March 2021; Accepted: 4 May 2021
References
 1. Ferguson, E. L., Varache, M., Stokniene, J. & Thomas, D. W. Polysaccharides for protein and peptide conjugation. In Polymer‑protein 
conjugates: From PEGylation and beyond Vol. 19 (eds Pasut, G. & Zaplinski, S.) 421–453 (Elsevier, New York, 2020).
 2. Ivens, I. A. et al. PEGylated biopharmaceuticals: Current experience and considerations for non-clinical development. Toxicol. 
Pathol. 43, 959–983. https:// doi. org/ 10. 1177/ 01926 23315 591171 (2015).
Table 2.  Characteristics of dextrin-colistin conjugates used in these studies. a measured using Viscotek TDA 
302 detector with 2 × Ultrahydrogel 250 columns.
Conjugate Mwa  (Mw/Mn) RHa (nm) Protein content (% w/w)
Molar ratio (x dextrin: 1 
colistin) Free protein (%)
Dextrin-colistin 1 mol%
29,600 (1.6) 2.6 5.8 2.9 2.1
21,700 (1.7) 2.5 7.4 2.2 7.0
Dextrin-colistin 2.5 mol%
30,300 (1.5) 2.7 6.4 2.6 2.4
23,000 (1.8) 2.6 9.3 1.7 4.5
Dextrin-colistin 7.5 mol%
59,800 (1.8) 3.2 14.0 1.1 0.7
74,900 (3.5) 3.5 18.1 0.8 1.5
11
Vol.:(0123456789)
Scientific Reports |        (2021) 11:10600  | https://doi.org/10.1038/s41598-021-89946-2
www.nature.com/scientificreports/
 3. Baumann, A., Tuerck, D., Prabhu, S., Dickmann, L. & Sims, J. Pharmacokinetics, metabolism and distribution of PEGs and 
PEGylated proteins: Quo vadis?. Drug Discov. Today 19, 1623–1631. https:// doi. org/ 10. 1016/j. drudis. 2014. 06. 002 (2014).
 4. Verhoef, J. J., Carpenter, J. F., Anchordoquy, T. J. & Schellekens, H. Potential induction of anti-PEG antibodies and complement 
activation toward PEGylated therapeutics. Drug Discov. Today 19, 1945–1952. https:// doi. org/ 10. 1016/j. drudis. 2014. 08. 015 (2014).
 5. Chi, C. C., Wang, S. H. & Kuo, T. T. Localized cutaneous polyvinylpyrrolidone storage disease mimicking cheilitis granulomatosa. 
J. Cutan. Pathol. 33, 454–457. https:// doi. org/ 10. 1111/j. 0303- 6987. 2006. 00476.x (2006).
 6. Ferguson, E. L., Azzopardi, E., Roberts, J. L., Walsh, T. R. & Thomas, D. W. Dextrin-colistin conjugates as a model bioresponsive 
treatment for multidrug resistant bacterial infections. Mol. Pharm. 11, 4437–4447. https:// doi. org/ 10. 1021/ mp500 584u (2014).
 7. Stokniene, J. et al. Bi-functional alginate oligosaccharide-polymyxin conjugates for improved treatment of multidrug-resistant 
Gram-negative bacterial infections. Pharmaceutics 12, 1080. https:// doi. org/ 10. 3390/ pharm aceut ics12 111080 (2020).
 8. Davies, D. S. Kinetics of icodextrin. Perit. Dial. Int. 14, S45-50. https:// doi. org/ 10. 1177/ 08968 60894 01402 S07 (1994).
 9. Duncan, R., Gilbert, H. R. P., Carbajo, R. J. & Vicent, M. J. Polymer masked-unmasked protein therapy (PUMPT) 1. Bioresponsive 
dextrin-trypsin and -MSH conjugates designed for α-amylase activation. Biomacromolecules 9, 1146–1154. https:// doi. org/ 10. 1021/ 
bm701 073n (2008).
 10. Hreczuk-Hirst, D., German, L. & Duncan, R. Dextrins as carriers for drug targeting: Reproducible succinoylation as a means to 
introduce pendant groups. J. Bioact. Compat. Polym. 16, 353–365. https:// doi. org/ 10. 1106/ QBKY- E3VM- 19K4- 3GA5 (2001).
 11. Li, J., Milne, R. W., Nation, R. L., Turnidge, J. D. & Coulthard, K. Stability of colistin and colistin methanesulfonate in aqueous 
media and plasma as determined by high-performance liquid chromatography. Antimicrob. Agents Chemother. 47, 1364–1370. 
https:// doi. org/ 10. 1128/ aac. 47.4. 1364- 1370. 2003 (2003).
 12. Healan, A. M. et al. Stability of colistimethate sodium in aqueous solution. Antimicrob. Agents Chemother. 56, 6432–6433. https:// 
doi. org/ 10. 1128/ AAC. 01079- 12 (2012).
 13. Wallace, S. J., Li, J., Rayner, C. R., Coulthard, K. & Nation, R. L. Stability of colistin methanesulfonate in pharmaceutical products 
and solutions for administration to patients. Antimicrob. Agents Chemother. 52, 3047–3051. https:// doi. org/ 10. 1128/ AAC. 00103- 08 
(2008).
 14. Le, J. et al. Consensus summary of aerosolized antimicrobial agents: Application of guideline criteria. Insights from the Society of 
Infectious Diseases Pharmacists. Pharmacotherapy 30, 562–584. https:// doi. org/ 10. 1592/ phco. 30.6. 562 (2010).
 15. Akinfemiwa, O. & Muniraj, T. Amylase In StatPearls (Statpearls Publishing, 2021).
 16. Whistler, R. L. & Bemiller, J. N. Alkaline degradation of polysaccharides. Adv. Carbohyd. Chem. 13, 289–329. https:// doi. org/ 10. 
1016/ S0096- 5332(08) 60359-8 (1958).
 17. Machell, G. & Richards, G. N. The alkaline degradation of polysaccharides 2 The alkali-stable residue from the action of sodium 
hydroxide on cellulose. J. Chem. Soc. https:// doi. org/ 10. 1039/ jr957 00045 00 (1957).
 18. Richards, G. N. & Sephton, H. H. 1957 The alkaline degradation of polysaccharides 1. Soluble products of the action of sodium 
hydroxide on cellulose. J. Chem. Soc. https:// doi. org/ 10. 1039/ jr957 00044 92 (1957).
 19. Varache, M. et al. Polymer masked-unmasked protein therapy: Identification of the active species after amylase activation of 
dextrin-colistin conjugates. Mol. Pharm. 16, 3199–3207. https:// doi. org/ 10. 1021/ acs. molph armac eut. 9b003 93 (2019).
 20. Li, J. et al. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl 
chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J. Chromatogr. 
B Biomed. Sci. Appl. 761, 167–175. https:// doi. org/ 10. 1016/ s0378- 4347(01) 00326-7 (2001).
 21. Li, J. et al. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatog-
raphy. Antimicrob. Agents Chemother. 46, 3304–3307. https:// doi. org/ 10. 1128/ aac. 46. 10. 3304- 3307. 2002 (2002).
 22. Chepyala, D., Tsai, I. L., Sun, H. Y., Lin, S. W. & Kuo, C. H. Development and validation of a high-performance liquid chromatog-
raphy-fluorescence detection method for the accurate quantification of colistin in human plasma. J. Chromatogr. B Analyt. Technol. 
Biomed. Life Sci. 980, 48–54. https:// doi. org/ 10. 1016/j. jchro mb. 2014. 12. 015 (2015).
 23. Hanai, Y. et al. Rapid, simple, and clinically applicable high-performance liquid chromatography method for clinical determination 
of plasma colistin concentrations. J. Pharm. Health Care Sci. 4, 22. https:// doi. org/ 10. 1186/ s40780- 018- 0119-x (2018).
 24. Bai, L., Ma, Z., Yang, G., Yang, J. & Cheng, J. A simple HPLC method for the separation of colistimethate sodium and colistin 
sulphate. J. Chromatogr. Sep. Tech. 2, 1000105. https:// doi. org/ 10. 4172/ 2157- 7064. 10001 05 (2011).
 25. Matar, K. M. & Al-Refai, B. Quantification of colistin in plasma by liquid chromatography-tandem mass spectrometry: Application 
to a pharmacokinetic study. Sci. Rep. 10, 8198. https:// doi. org/ 10. 1038/ s41598- 020- 65041-w (2020).
 26. Zhao, M. et al. LC-MS/MS determination of colistin in Mueller-Hinton broth for in vitro pharmacodynamic studies. J. Antibiot. 
67, 825–829. https:// doi. org/ 10. 1038/ ja. 2014. 73 (2014).
 27. Gobin, P., Lemaitre, F., Marchand, S., Couet, W. & Olivier, J. C. Assay of colistin and colistin methanesulfonate in plasma and urine 
by liquid chromatography-tandem mass spectrometry. Antimicrob. Agents Chemother. 54, 1941–1948. https:// doi. org/ 10. 1128/ Aac. 
01367- 09 (2010).
 28. Calixto, G. et al. Microbiological assay for the determination of colistin sulphate. Curr. Anal. Chem. 10, 443–448. https:// doi. org/ 
10. 2174/ 15734 11011 30909 90017 (2014).
 29. Wootton, M., Holt, H. A. & MacGowan, A. P. Development of a novel assay method for colistin sulphomethate. Clin. Microbiol. 
Infect. 11, 243–244. https:// doi. org/ 10. 1111/j. 1469- 0691. 2005. 01076.x (2005).
 30. Gaudin, V., Hedou, C., Rault, A., Verdon, E. & Soumet, C. Evaluation of three ELISA kits for the screening of colistin residue in 
porcine and poultry muscle according to the European guideline for the validation of screening methods. Food Addit. Contam. 
Part A Chem. Anal. Control Expo. Risk Assess. 37, 1651–1666. https:// doi. org/ 10. 1080/ 19440 049. 2020. 17781 91 (2020).
 31. Elimam, M. M., Shantier, S. W., Gadkariem, E. A. & Mohamed, M. A. Derivative spectrophotometric methods for the analysis and 
stability studies of colistin sulphate. J. Chem. https:// doi. org/ 10. 1155/ 2015/ 624316 (2015).
 32. Saraiva, M. A. Interpretation of alpha-synuclein UV absorption spectra in the peptide bond and the aromatic regions. J. Photochem. 
Photobiol. B. https:// doi. org/ 10. 1016/j. jphot obiol. 2020. 112022 (2020).
 33. Khan, S. et al. Overcoming drug resistance with alginate oligosaccharides able to potentiate the action of selected antibiotics. 
Antimicrob. Agents chemother. 56, 5134–5141. https:// doi. org/ 10. 1128/ AAC. 00525- 12 (2012).
 34. Jorgensen, J. H. & Turnidge, J. D. Susceptibility test methods: Dilution and disk diffusion methods. In Manual of Clinical Microbiol‑
ogy Vol. 71 (eds Jorgensen, J. H. et al.) 1253–1273 (ASM Press, Washington, 2015).
Acknowledgements
This work was supported by research grants from the Royal Society (RGS/R2/180069) and the UK Medical 
Research Council (MR/N023633/1). The authors thank Dr Konrad Beck for useful scientific discussions that 
contributed to data interpretation.
Author contributions
Conceptualization, M.V., D.W.T., E.L.F.; Investigation, E.C., M.V., J.S., E.L.F.; Formal analysis, E.C., J.S., E.L.F.; 
Writing-Review and editing, M.V., J.S., D.W.T., E.L.F. All authors read and approved the final manuscript.
12
Vol:.(1234567890)
Scientific Reports |        (2021) 11:10600  | https://doi.org/10.1038/s41598-021-89946-2
www.nature.com/scientificreports/
Competing interests 
The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 
10. 1038/ s41598- 021- 89946-2.
Correspondence and requests for materials should be addressed to E.L.F.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
© The Author(s) 2021
